JP2006525288A - アルツハイマー病治療方法 - Google Patents

アルツハイマー病治療方法 Download PDF

Info

Publication number
JP2006525288A
JP2006525288A JP2006505607A JP2006505607A JP2006525288A JP 2006525288 A JP2006525288 A JP 2006525288A JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006525288 A JP2006525288 A JP 2006525288A
Authority
JP
Japan
Prior art keywords
peptide
seq
peptides
terminal
resulting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006505607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525288A5 (es
Inventor
バーリオ マニュエル サラサ
Original Assignee
ユニバーシダッド デ ザラゴザ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシダッド デ ザラゴザ filed Critical ユニバーシダッド デ ザラゴザ
Publication of JP2006525288A publication Critical patent/JP2006525288A/ja
Publication of JP2006525288A5 publication Critical patent/JP2006525288A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
JP2006505607A 2003-05-08 2004-05-03 アルツハイマー病治療方法 Pending JP2006525288A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011191515A Division JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Division JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法

Publications (2)

Publication Number Publication Date
JP2006525288A true JP2006525288A (ja) 2006-11-09
JP2006525288A5 JP2006525288A5 (es) 2007-02-08

Family

ID=32982086

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006505607A Pending JP2006525288A (ja) 2003-05-08 2004-05-03 アルツハイマー病治療方法
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Country Status (19)

Country Link
US (6) US20090162362A1 (es)
EP (5) EP2305286A3 (es)
JP (5) JP2006525288A (es)
CN (2) CN1784240A (es)
AT (1) ATE435024T1 (es)
AU (2) AU2004237373A1 (es)
BR (1) BRPI0410684A (es)
CA (1) CA2524571C (es)
CY (1) CY1109454T1 (es)
DE (1) DE602004021797D1 (es)
DK (3) DK2075007T3 (es)
ES (6) ES2246178B1 (es)
IL (8) IL171651A (es)
MX (1) MXPA05010914A (es)
PL (3) PL2075007T3 (es)
PT (3) PT2075007E (es)
RU (2) RU2385161C2 (es)
SI (1) SI1623719T1 (es)
WO (1) WO2004098631A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CA2632822C (en) * 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
WO2008011348A2 (en) * 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2009048539A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
HUE028105T2 (en) 2009-12-11 2016-11-28 Araclon Biotech Sl Methods and Reagents for Improved Detection of Beta-Amyloid Peptides
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
CA2805414C (en) * 2010-07-14 2020-07-07 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072880A2 (en) * 1999-05-28 2000-12-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
AU759945B2 (en) * 1998-08-20 2003-05-01 Regents Of The University Of California, The Methods for labeling beta-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070128191A1 (en) * 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置
WO2000072880A2 (en) * 1999-05-28 2000-12-07 Neuralab Limited Prevention and treatment of amyloidogenic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HELENE BARELLI, MOLECULAR MEDICINE, vol. 3, no. 10, JPN6010015697, 1997, pages 695 - 707, ISSN: 0001576481 *

Also Published As

Publication number Publication date
ES2246105B1 (es) 2007-03-01
IL207875A (en) 2013-02-28
EP2075007B9 (en) 2013-09-04
EP1623719A1 (en) 2006-02-08
EP2082747A2 (en) 2009-07-29
PT2075007E (pt) 2013-08-23
ES2246105A1 (es) 2006-02-01
RU2526155C2 (ru) 2014-08-20
JP2012006967A (ja) 2012-01-12
IL207877A (en) 2013-03-24
IL207879A0 (en) 2011-07-31
IL171651A (en) 2011-11-30
PL1623719T3 (pl) 2010-11-30
DK2075007T3 (da) 2013-07-29
JP2014129389A (ja) 2014-07-10
EP2075007A2 (en) 2009-07-01
ES2423590T3 (es) 2013-09-23
IL207876A (en) 2013-03-24
EP2305286A2 (en) 2011-04-06
ATE435024T1 (de) 2009-07-15
AU2011200170A1 (en) 2011-02-03
IL207879A (en) 2013-02-28
EP2305286A3 (en) 2011-11-09
IL207877A0 (en) 2011-07-31
IL207875A0 (en) 2011-07-31
EP2356996B9 (en) 2013-08-28
EP1623719B1 (en) 2009-07-01
AU2011200170C1 (en) 2012-03-22
CA2524571A1 (en) 2004-11-18
CN101264326A (zh) 2008-09-17
RU2005134351A (ru) 2006-04-27
EP2082747A3 (en) 2010-01-13
DK1623719T3 (da) 2009-11-09
EP2075007B1 (en) 2013-05-22
MXPA05010914A (es) 2006-03-21
EP2075007A3 (en) 2009-11-11
ES2423281T3 (es) 2013-09-19
ES2246177A1 (es) 2006-02-01
US20210214394A1 (en) 2021-07-15
IL207881A0 (en) 2011-07-31
IL207880A0 (en) 2011-07-31
EP2356996A1 (en) 2011-08-17
AU2011200170B2 (en) 2011-09-01
US20140044725A1 (en) 2014-02-13
PL2356996T3 (pl) 2013-09-30
SI1623719T1 (sl) 2009-12-31
IL207878A0 (en) 2011-07-31
JP2018119011A (ja) 2018-08-02
IL207878A (en) 2013-02-28
IL207876A0 (en) 2011-07-31
JP2016065100A (ja) 2016-04-28
ES2246177B1 (es) 2007-03-01
EP2356996B1 (en) 2013-06-26
PT2356996E (pt) 2013-08-23
CA2524571C (en) 2017-01-10
CN1784240A (zh) 2006-06-07
US20110262458A1 (en) 2011-10-27
ES2329369T3 (es) 2009-11-25
ES2246178A1 (es) 2006-02-01
US20200140488A1 (en) 2020-05-07
DK2356996T5 (da) 2013-08-26
RU2009148539A (ru) 2011-06-27
RU2385161C2 (ru) 2010-03-27
US20170260234A1 (en) 2017-09-14
WO2004098631A1 (es) 2004-11-18
IL207880A (en) 2013-02-28
IL207881A (en) 2013-02-28
AU2004237373A1 (en) 2004-11-18
PL2075007T3 (pl) 2013-09-30
CY1109454T1 (el) 2014-08-13
PT1623719E (pt) 2009-10-08
US20090162362A1 (en) 2009-06-25
DK2356996T3 (da) 2013-07-22
DE602004021797D1 (de) 2009-08-13
BRPI0410684A (pt) 2006-06-20
ES2246178B1 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
JP2018119011A (ja) アルツハイマー病治療方法
AU2011226926A1 (en) Alzheimer's disease treatment method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100707

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110902

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110926

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130625